Conditions: Rhinitis, Allergic, Perennial Rhinitis, Allergic, Nonseasonal
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 124
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the dose-related effectiveness, the safety and the tolerability of MK-8237, compared to placebo, in the treatment of house dust mite (HDM)-induced allergic rhinitis/rhinoconjunctivitis in adults. The primary hypothesis is that administration of MK-8237, compared to placebo, results in dose-related improvement in the average total nasal symptom score (TNSS) determined during environmental exposure chamber (EEC) challenge.

Detailed description:

Arms:
arm 1: Placebo rapidly dissolving tablet administered sublingually once daily (q.d.), at approximately the same time each day, for 24 weeks arm 2: MK-8237 6 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks arm 3: MK-8237 12 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks

Interventions: intervention 1: Placebo intervention 2: MK-8237 6 DU intervention 3: MK-8237 12 DU
Intervention descriptions: intervention 1: Placebo rapidly dissolving tablets administered sublingually once daily intervention 2: MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily intervention 3: MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily

Protocol document: